Exhibit 10.21


 








TECHNOLOGY LICENSE AGREEMENT


 


THIS AGREEMENT is
made as of this 27th day of February 2012 ("Effective Date") by and between Fuse Science Inc., a Delaware corporation,
("Fuse Science" or "LICENSOR") having its principal offices located at 6135 NW 167th Street, Suite E-21, Miami
Lakes, FL 33015 and Mission Product Holdings, Inc., (“Mission of “LICENSEE”) having its principal place of business
at 185 Madison Ave., 12th Floor, New York, NY 10016 (individually, a "Party," and collectively the "Parties").


 


WITNESSETH:


 


WHEREAS, LICENSOR
has certain ownership and exclusive right, pursuant to a licensing agreement dated September 15, 2011 ("Licensing Agreement")
with Cure IP Holdings LLC ("Cure IP") to provisional patent application rights, patent pending rights, patent rights,
trade secrets, know-how and related proprietary information directed t. certain formulations for bioactive agents, including but
not limited to transdermal and sublingual absorbed compositions (such Cure IP that is provided to LICENSEE hereunder is hereinafter
re cl to as the "Subject Technology");


 


WHEREAS, Cure IP has
filed certain pending patent applications with regard to the Subject Technology including but not limited to Provisional Patent
Application Serial Number 61/533,278 filed on or about September 12, 2011 before the United States Patent & Trademark Office
(“USPTO”);


 


WHEREAS, Cure IP has
developed and exclusively licensed the Subject Technology to LICENSOR certain proprietary formulations with regard to
u inactive agents for transdermal and sublingual application that may have benefit with athletic skin care preparations;


 


WHEREAS, LICENSOR
has established certain manufacturing and research & development relationships with Cure Pharmaceuticals Inc. located in Oxnard,
California, through its written agreements with Cure IP, to create drug delivery systems for use in administering nutraceutical
and pharmaceutical compositions based upon the Subject Technology for purposes of creating proprietary components and additions
to athletic skin care preparations;


 


WHEREAS, LICENSEE
sells, markets, advertises, promotes and distributes athletic skin care and other preparations, including but not limited to sun
block preparations, skin moisturizers, foot creams, muscle rubs and lip care products;


 


WHEREAS, LICENSEE has relations with various
retailers, distributors, wholesalers and on-line outlets for the purposes of selling athletic skin care preparations;


 


WHEREAS, LICENSEE
desires to license and have benefit to certain portions of the intellectual property relating to the Subject Technology, including
pending patent applications, know-how, and related proprietary information regarding these formulations for bioactive agents for
application with athletic skin care preparations via sublingual absorption modalities;


 



    	 



    	 



    

 


CONFIDENTIAL AND PROPRIETARY  


 


WHEREAS, LICENSEE
would like the benefit of having LICENSOR manufacture and supply certain drug delivery systems based upon the Subject Technology
on behalf of the LICENSEE; and


 


WHEREAS, LICENSOR
desires to allow LICENSEE to employ and include certain formulations in LICENSEE's skin care preparations.


 


NOW, THERE.PORE, in
consideration of the premises and the mutual covenants of this Agreement, the parties hereto agree as follows:


 


I.           LICENSE
GRANT


 


A.           Scope
of License: LICENSOR hereby grants to LICENSEE for the Term of this Agreement as defined below, a restricted right to use, include,
provide, distribute, advertise, promote, sell and offer for sale athletic skin care preparations that include formulations based
upon the Subject Technology. Accordingly, LICENSOR grants LICENSE the right to include bioactive agents that are based upon the
Subject Technology f purposes of offering drug delivery systems for administering OTC compositions through transdermal transfer
in the sports application positioning of the Mission Athletecare brand.


 


B.           Non-Exclusive
Rights to Patents and Patent Pending Right: LICENSEE shall have rights under LICENSOR’s exclusive rights to any and all patents,
pending patent applications, provisional patent applications, divisonals, continuation, and continuation-in-part applications both
in the United States, and any foreign patent rights including PCT patent applications that have been filed by the Effective Date
and assigned to Cure IP (and licensed through the License Agreement from Cure IP.


 


C.           Rights
to Proprietary Information: LICENSEE shall have full rights to LICENSOR’s proprietary information relating to the formulations
based upon the Subject Technology. LICENSEE shall have direct rights and access to LICENSOR’s trade secrets, know-how, or
internal proprietary information with regard to the Subject Technology, including but not limited to formulations, chemical compositions,
or methods of preparation to the extent such information is necessary for LICENSEE to exploit Subject Technology. Any such information
obtained by LICENSEE for purposed of commercializing and adding the Subject Technology to LICENSEE’s athletic skin care preparation
shall be based upon LICENSEE’s strict duty of confidentiality with regard to this information, as proscribed in Section IV
defined below.


 


D.           Rights
to New Formulations, Improved Formulas and Modified Bioactive Agents: LICENSEE shall have rights to benefit from and receive from
LICENSOR any new formulations, improved and modified formulas and advanced bioactive agents based upon the Subject Technology for
purposes of introduction in LICENSEE's athletic skin care preparations.


 



    	 



    	 



    

 


CONFIDENTIAL AND PROPRIETARY


 


E.           Rights
to Use Trademarks: LICENSEE shall have limited rights to use the name FUSE SCIENCE and any related registered or unregistered indicia,
slogans, marks, trade names or trade dress owned by LICENSOR for the limited purpose of accurately reflecting this affiliation
and relationship. However, LICENSEE shall confirm to LICENSOR's strict quality control guidelines and be subject to periodic
inspections by LICENSOR Likewise, subject to written approval by LICENSEE, such approval not be unreasonably withheld, LICENSOR
shall have reciprocal rights to use any of LICENSEE's names, trademarks, registered or unregistered indicia, slogans, marks, trade
names or trade dress owned by LICENSOR for the limited purpose of accurately reflecting this affiliation and relationship. However,
LICENSOR and LICENSEE respectively, shall cease such usage upon the termination of this Agreement and any such usage by LICENSOR
or LICENSEE be subject to and shall conform to LICENSEE's or LICENSOR's trademark usage standards, it being understood that LICENSOR
and LICENSEE shall promptly cease any usage that LICENSOR or LICENSEE determines to be non-conforming.


 


F.           Geographic
Scope: The geographic scope hereby granted by LICENSOR to LICENSEE regarding the rights articulated in Paragraph A above
shall be worldwide (the "Territory"). Accordingly, such grant shall include rights to not only patents (and pending patent
applications) filed and/or issued before the 12,SPTO, but also any worldwide patents, pending patent applications, PCT applications
or any applications filed through any recognized foreign administrative agency or body.


 


G.           For
the avoidance of doubt and notwithstanding the foregoing or any other provision herein, this Agreement does not impose upon LICENSEE
any obligation to exercise the rights granted in the foregoing license, to manufacture Licensed Products, or to otherwise exploit
the Subject Technology in any way, it being understood that such decisions will be made by LICENSEE in its sole discretion.


 


H.           LICENSOR
Rights: LICENSOR hereby represents and warrants that LICENSOR has all necessary right, title and interest to grant the rights and
licenses hereunder and that the exercise of such rights and licenses by LICENSEE will not infringe upon or violate the rights of
any third party.


 


II.          TERM
OF AGREEMENT


 


A.           Contemplated
Term: Unless otherwise terminated in accordance with the terms and conditions of this Agreement, this limited and non-exclusive
license as to the Subject Technology shall have a four (4) ear following term commencing on the Effective Date as identified herein
above (the “Term”) with mutually agreed renewal terms.


  



    	 



    	 



    

 


CONFIDENTIAL AND PROPRIETARY


 


III.         COMPENSATION


 


A.           Royalty
Based upon Sales of Products: LICENSEE agrees to pay LICENSOR a reasonable royalty based upon 9.0% of Net Sales (the “Royalty”)
received by LICENSEE regarding any and all sales of LICENSEE’s products which include as their main composition the Subject
Technology. This shall include only sublingual absorption delivery systems based upon, fall within any of the claims, or include
any of LICENSOR's patented or patent pending technology related to sublingual absorption modalities.


 


B.           Endorser-Related
Royalty Offset: LICENSEE shall be entitled to deduct and retain from the Royalty amount set forth in subsection A herein above,
such amounts as are pre-approved by LICENSOR in connection with certain products in order to accommodate certain endorsement arrangements
on a case-by-case basis to be mutually agreed upon by the Parties, provided however, that in no event shall such deduction exceed
1.5% of the Royalty amount owed to LICENSOR pursuant to subsection A herein above.


 


C.           Quarterly
Royalty Period: The Royalty owed LICENSOR shall be calculated on a quarterly calendar basis (the "Royalty Period") and
shall be payable no later than thirty (30) days after the termination of the preceding full quarter period, i.e.,
commencing on the first (1st) day of January, April, July, and October, except that the first and last calendar periods may need
to be pro-rated depending on the effective date of this Agreement


 


D.           Detailed
Reporting for Each Royalty Period: For each Royalty Period, LICENSEE shall provide LICENSOR with a written royalty statement in
a form reasonably acceptable to LICENSOR Such royalty statement shall be certified as accurate by a duly authorized officer of
LICENSEE reciting, on a country by country basis, the stock number, item, units sold, description, quantity shipped, gross invoice,
amount billed customers less discounts, allowances, returns and reportable sales for each Licensed Product. Such statements shall
be furnished to LICENSOR only if Licensed Products were sold during the Royalty Period and only to the extent any actual Royalty
is owed.


 


E.           Definition
of "Net Sales" for Royalty Calculation: "Net Sates" shall mean LICENSEE's gross sales (the gross invoice amount
billed customers) of Licensed Products, less discounts and allowances actually shown on the invoice and, further, less any bona
fide returns (net of all returns actually made or allowed as supported by credit memoranda actually issued to the customers) up
to the amount of the actual sales of the Licensed Products during the Royalty Period. No other costs incurred in the manufacturing,
selling, advertising, and distribution of the Licensed Products shall be deducted nor shall any deduction be allowed for any uncollectible
accounts or allowances-


 


F.           Royalty
Obligation Occurs Upon Sale: A Royalty obligation shall accrue upon the sale of the Licensed Products (herein defined as any athletic
skin care product or preparation based upon or which includes the Subject Technology) regardless of the time of collection by LICENSEE.
A Licensed Product shall be considered "sold" when such Licensed Product is billed, invoiced, shipped, or paid for, whichever
occurs first


 



    	 



    	 



    

 


CONFIDENTIAL AND PROPRIETARY


 





G.           Receipt
No Waiver to Challenge Statement Accuracy: The receipt or acceptance by LICENSOR of any royalty statement or payment shall not
prevent LICENSOR from subsequently challenging the validity or accuracy of such statement or payment, Survival of Payment Obligations:
LICENSEE'S obligations for the payment of Royalties shall survive expiration or termination of this Agreement and will continue
for so long as LICENSEE continues to sell the Licensed Products.


 


H.           Survival
of Payment Obligations: LICENSEE’S obligations for the payment of Royalties shall survive expiration or termination of this
Agreement and will continue for so long as LICENSEE continues to sell the Licensed Products.


 


I.            Payments
Made in U.S Currency: All payments due LICENSOR shall be made in United States currency by check drawn on a United States bank,
unless otherwise specified by LICENSOR


 


J.           Warrant:
Upon the execution of this Agreement, LICENSEE will issue to LICENSOR a warrant to purchase Five Hundred Thousand (500,000) shares
of LICENSEE's common stock (the "Shares") for a purchase price of $9.00 per share in the form attached hereto as Exhibit
A.


 


IV.         CONFIDENTIALITY OBLIGATIONS


 


A.Access to
Confidential Information: LICENSEE recognizes that during the course of preparing, mixing, adding, employing and making the various
athletic skin preparations based upon or derived from the Subject Technology that LICENSEE may have occasion to review, receive
and have access to confidential materials from LICENSOR with regard to certain bioactive agents, which includes information relating
to drug delivery systems for use in administering nutraceutical and pharmaceutical compositions, patentable ideas, improvements,
specifications, cost and pricing data, investor information, capital raises, client information, customer and vendor lists, and
any other related material used in the ordinary course of business at LICENSOR which may be material to the on-going business of
LICENSOR, its clients, or related third-parties which have an actual or potential relationship with LICENSOR ("Confidential
Information").


 


B.           Acknowledgement
of Trade Secrets: The Parties agree that the Confidential Information may constitute a trade secret of value owned solely by LICENSOR
which is of advantage to it, or which provides advantage to it over those who do not know such Confidential Information and is
otherwise deemed confidential, proprietary information pursuant to applicable Florida law, including, but not limited to Florida
Statute §812.081. LICENSOR acknowledges that the Confidential Information is a valuable, special and unique asset and property
right exclusively owned by LICENSOR, whether patentable or not.


 



    	 



    	 



    

 


C.           Retaining
the Confidential Information: LICENSEE covenants and agrees that both during and after termination of this Agreement, LICENSEE
shall retain such Confidential Information in confidence pursuant to the following leans and conditions: LICENSEE further agrees
to maintain in confidence any such Confidential Information disclosed by LICENSOR or any actual or potential client of LICENSOR
that was not previously known to LICENSEE or to the general public, or that was not in the public domain prior to such disclosure.
Such Confidential Information shall be maintained in confidence by LICENSEEunless or until:


 


		i.	It shall have been made public by an act or omission
of a Party other than LICENSEE



 


		ii.	LICENSEE receives such Confidential Information from
an unrelated third party on a non-confidential basis; or



 


		iii.	The passage of ten (10) years from the date of disclosure,
whichever shall first occur,



 


D.           Prompt
Return of Confidential Materials: Upon request (but subject in all cases to Section XI below), LICENSEE agrees to promptly return
to LICENSOR any materials obtained from or through LICENSOR including all memoranda, drawings, formulations, design or utility
patent applications (or subject matter relating to such applications), specifications, and process or flow diagrams including any
copies, notes, or memoranda made by LICENSEE, in any way, include Confidential Information disclosed or transmitted to LICENSEE
by LICENSOR. Such prompt return shall include any and all known computer data, computer files, .PDFs, .JPGs, entails and any related
electronically stored information within LICENSEE'S control that resides on any CDs, hard drives, flash drives, disks, iPods, digital
music players or related memory devices whether owned by LICENSOR, LICENSEE or any third-party related to LICENSEE (including but
not limited to personal computer devices). Upon such request,. LICENSEE shall, to the best of its knowledge, stipulate to such
removal of electronically stored information as well as performance of any such reasonable steps to ensure complete removal of
such data, including any necessary digital wiping (including use of any readily available wiping software) to ensure complete removal
of the requested data.


 


Except to the extent within the scope of
or otherwise permitted milder the rights and licenses granted herein, LICENSEE agrees that it will not, without first obtaining
the prior written permission of LICENSOR:


 


		i.	Directly or indirectly utilize such Confidential Information
in its business, except as otherwise provided for herein;



 


		ii.	Develop, program, code, create or launch any design,
engineering, product development or related consumer product offering that is based in whole or in part of any subject matter
which touches upon, is related to, or could be remotely derived from the Confidential Information; or



 



    	 



    	 



    

 


CONFIDENTIAL AND PROPRIETARY


 


		iii.	Disclose such Confidential Information to any third party,
whether or not a competitor to LICENSOR, a potential or actual client of LICENSOR or related third-party (including any potential
investors, advisors or affiliates of LICENSOR).



 


Neither party shall originate any publicity,
news release, or other public announcement, written or oral, relating to this Agreement, to performance hereunder, or to any matter
relating to the other party without the prior written approval of the other party.


 


E.           Restriction
Against Reverse Engineering: LICENSEE agrees that it will not attempt, either directly or indirectly, to reverse engineer any of
LICENSOR's bioactive agents, formulations, or related preparations.


 


F.           Right
to Injunctive Relief: LICENSEE agrees that the restrictions set forth in this Agreement are just and reasonable. In the event that
LICENSEE violates, breaches or threatens to breach any of the covenants or restrictions contained herein, LICENSEE acknowledges
that:


 


		a.	LICENSOR will suffer immediate, irreparable, actual and
substantial harm resulting in LICENSOR's lost business, business interruption, administrative expenses and lost profits; and



 


		b.	It may be impossible to ascertain the amount of such
damages with any reasonable degree of accuracy.



 


In the event that LICENSEE violates or
breaches any of the restrictions or covenants contained herein, or threatens such a breach or violation, LICENSOR shall be entitled
to seek immediate, temporary and permanent injunction and other equitable relief to enforce any and all of the provisions set forth
herein in a court of competent jurisdiction. In addition to or in lieu of the above, LICENSOR may, in its sole discretion, pursue
any and all other remedies available to it for such violation, breath or threatened breach, including recovery of compensatory
damages.


  



    	 



    	 



    

 


CONFIDENTIAL AND PROPRIETARY


 


V.         DUTY TO ASSIGN IMPROVEMENTS


 


 


A.           Duty
to Assign Inventions and Works of Authorship: Any inventions, improvements, concepts, works of authorship or ideas made or conceived
by LICENSEE during or in connection with any business performed under this Agreement (or twenty four (24) months thereafter) based
upon the disclosure by LICENSOR (or any entity related to Cure IP or Cure Pharmaceuticals) of any trade secrets, proprietary information,
know-how or formulations with regard to athletic skin preparations based upon the Subject Technology (the "Work"), including
information disclosed in Provisional Patent Application Serial Number 61/533,228, shall be considered the sole and exclusive property
of LICENSOR. LICENSEE shall promptly and fully report and disclose all such Work to LICENSOR (including after termination or expiration
of this Agreement). Any Work performed by LICENSEE under this Agreement shall be considered a 'Work Made for Hire" as that
phrase is defined by the U.S. Copyright laws and shall be owned by and for the express benefit of LICENSOR. In the event it should
be established that such work does not qualify as a Work Made for Hire, LICENSEE agrees to and does hereby assign to LICENSOR
all of his right, title, and interest in such work product, including but not limited to all copyrights, patents, trademarks,
and other proprietary rights. LICENSEE expressly hereby assigns any and all patent and invention rights to any Work developed
during the Term relating directly or indirectly to the business of LICENSOR


 


B.           Duty
to Cooperate with Creation of Patent Applications: Both during the Term of this Agreement and thereafter, LICENSEE shall (at LICENSOR's
sole expense) fully cooperate with LICENSOR in the protection (including drafting and preparation of any applications), prosecution
(including execution of any declarations and correspondence to any government agency), licensing and enforcement of any intellectual
property rights that may derive as a result of the services performed by LICENSEE under the terms of this Agreement. This shall
include executing, acknowledging, and delivering to LICENSOR all documents or papers that may be necessary to enable LICENSOR to
publish or protect said inventions, improvements, and ideas in the name of LICENSOR, its clients, or any related third-parties.


 


VI.           RECORD INSPECTION AND AUDIT


 


A.           Right
to Inspect: LICENSOR shall have the right, upon reasonable notice, to inspect LICENSEE's books and records and all other documents
and material in LICENSEE's possession or control that relate directly to the sales of the Licensed Products.


 


B.           Accessibility
of Books and Records: All books and records relative to LICENSEE's obligations that relate directly to the sales of Licensed Products
shall be maintained and made accessible to LICENSOR for inspection at a location in the United States for at least three (3) years
after termination of this Agreement.


 


VII.           LICENSEE'S OBLIGATIONS


 


A.           Compliance
with Marking Provisions: LICENSEE shall fully comply with the


marking provisions of the intellectual
property laws of the applicable countries in the Licensed Territory.


 


VIII.         
EXPORT CONTROL


 


Anything contained
in this Agreement to the contrary notwithstanding, the obligations of the parties hereto and of the subsidiaries of the parties
shall be subject to all laws, present and future and including export control laws and regulations, of any government having jurisdiction
over the parties hereto or the subsidiaries of the parties, and to orders, regulations, directions or requests of any such government.
Each party shall undertake to comply with and be solely responsible for complying with such laws applicable to such party.


 



    	 



    	 



    

 


CONFIDENTIAL AND PROPRIETARY





 


IX.         TAXES AND GOVERNMENTAL APPROVALS


 


A.           Licensee
to Pay Taxes and Duties: LICENSEE shall be solely responsible for the payment of any and all taxes, fees, duties and other payments
incurred in relation to its manufacture, use and sale of the systems and methods of the Patents or Licensed Products with the exception
that LICENSOR shall be solely responsible for the payment of any and all taxes, fees, duties or other payments assessed by all
relevant authorities by virtue of Cure IP being the owner of the Patents.


 


B.           Licensee
to Pay Approvals and Validations: LICENSEE shall be solely responsible for applying for and obtaining any approvals, authorizations,
or validations necessary to effectuate the terms of this Agreement under the laws of the appropriate national laws of each of the
countries in the Licensed Territory.


 


X.         TERMINATION


 


The following termination
rights are in addition to the termination rights which may be provided elsewhere in the Agreement:


 


A.           Immediate
Right of Termination. LICENSOR shall have the right to immediately terminate this Agreement by giving written notice to LICENSEE
in the event that LICENSEE does any of the following:


 


1. Fails to obtain
or maintain product liability insurance in the amount and of the type provided for herein; or


 


2. Files a petition
in bankruptcy or is adjudicated a bankrupt or insolvent, or makes an assignment for the benefit of creditors or an arrangement
pursuant to any bankruptcy law, or if the LICENSEE discontinues or dissolves its business or if a receiver is appointed for LICENSEE
or for LICENSEE's business and such receiver is not discharged within thirty (30) days.


 


B.           Right
to Terminate on Notice. Either party may terminate this Agreement on ninety (90) days written notice to the other party in the
event of a breach of any provision of this Agreement by the other party, provided that, during the ninety (90) day period, the
breaching party fails to cure such breach


 


C.           LICENSEE
Right to Terminate. The LICENSEE shall have the right to terminate this Agreement after January I, 2013 by providing ten (10) days
written notice to LICENSOR for any reason.


 



    	 



    	 



    

  


CONFIDENTIAL AND PROPRIETARY


 


XI         POST
TERMINATION RIGHTS


 


A.           Subject
to the Sell-Off Rights below, upon the expiration or termination of this Agreement, all rights granted to LICENSEE under this Agreement
shall forthwith terminate and immediately revert to LICENSOR and LICENSEE shall discontinue all use of the Subject Technology and
the like_


 


B.           Upon
the expiration or termination of this Agreement, LICENSOR may require that the LICENSEE transmit to LICENSOR, at no cost, all material
relating to the Subject Technology, provided, however, that LICENSEE shall be permitted to retain a full copy of all material subject
to the confidentiality provisions of this agreement


 


C.           In
the event that the Licensing Agreement is terminated through no fault of LICENSEE, by signing this Agreement, Cure IP Holdings,
LLC hereby covenants and agrees that they shall enter into a direct relationship with LICENSEE on substantially the same terms
as contained herein.


 


D.           Notwithstanding
the foregoing or any other provision herein to the contrary, LICENSEE shall have a period of not less than nine (9) calendar months
following the effective date of this Agreement (-Sell-Off Period") to distrittite and sell any Licensed Products
that have been manufactured, in whole or in part, prior to the effective date of termination ("Sell-Off Rights"), it
being understood that LICENSEE shall not be in. breach of this Agreement or otherwise liable in any manner with respect to the
sale or distribution of Licensed Products by its customers following the Sell-Off Period.


 


XII.         INSURANCE


 


Should LICENSEE elect
to produce any Licensed Products that are subject to a royalty hereunder, LICENSEE shall, prior to the manufacture of such Licensed
Products, obtain and maintain at its own cost and expense from a qualified insurance company licensed to do business in New York
and having a Moody's rating of B- or better, standard Product Liability Insurance naming LICENSOR, and its officers, directors,
employees, agents, and shareholders,, as an additional insured. Such policy shall provide protection against all claims, demands,
and causes of action arising out of any defects or failure to perform, alleged or otherwise, of the Licensed Products or
any material used in connection therewith or any use thereof. The amount of coverage shall be not less than $2,000,000 per claim.
The policy shall provide for thirty (30) days' notice to LICENSOR from the insurer by reps' tered or certified mail, return receipt
requested, in the event of any modification, cancellation, or termination thereof. LICENSEE agrees to furnish LICENSOR a certificate
of insurance evidencing same within thirty (30) days after it begins production of any Licensed Products and, in no event, shall
LICENSEE manufacture, distribute, or sell the Licensed Products prior to receipt by LICENSOR. of such evidence of insurance.


 



    	 



    	 



    

  


CONFIDENTIAL AND PROPRIETARY


 


XIII.         FORCE
MAJEURE


 


Neither party will
be liable for or will be considered to be in breach of or default under this Agreement on account of any delay or failure to perform
as required by this Agreement as a result of any causes or conditions that are beyond such Party's reasonable control and that
such Party is unable to overcome through the exercise of commercially reasonable diligence. If any force majeure event occurs,
the affected Party will give prompt written notice to the other Party and will use commercially reasonable efforts to minimize
the impact of the event.


 


XIV.         NOTICE AND PAYMENT


 


  A.           Any
notice required to be given under this Agreement shall be in writing and delivered personally to the other designated party at
the above stated address or mailed by certified, registered or Express mail, return receipt requested or by Federal Express.


 


  B.           Either
party may change the address to which notice or payment is to be sent by written notice to the other under any provision of this
paragraph.


 


XV.          JURISDICTION/DISPUTES


 


 This Agreement shall
be governed in accordance with the laws of the State of New York.


 


XVI.        AGREEMENT BINDING ON SUCCESSORS


 


The provisions of the
Agreement shall be binding upon and shall inure to the benefit of the Parties hereto, their heirs, administrators, successors and
assigns.


 


XVII.       ASSIGNABILITY


 


Except in connection
with a change of control event, neither party may assign this Agreement or the rights and obligations thereunder to any third party
without the prior express written approval of the other party which shall not be unreasonably withheld.


 


XVIII.         WAIVER


 


No waiver by either
party of any default shall be deemed as a waiver of prior or subsequent default of the same of other provisions of this Agreement


 


XVIII.         SEVERA,BILITY


 


If any term, clause
or provision hereof is held invalid or unenforceable by a court of competent jurisdiction, such invalidity shall not affect the
validity or operation of any other term, clause or provision and such invalid term, clause or provision shall be deemed to be severed
from the Agreement


 



    	 



    	 



    

 


CONFIDENTIAL AND PROPRIETARY





 


XIX.         INTEGRATION


 


This Agreement constitutes
the entire understanding of the Parties, and revokes and supersedes all prior agreements between the Parties and is intended as
a final expression of their Agreement. It shall not be modified or amended except in writing signed by the Parties hereto and specifically
referring to this Agreement This Agreement shall take precedence over any other documents which may conflict with this Agreement


 


XX         COMPETITION


 


Nothing in this Agreement
shall prohibit LICENSEE from entering into license agreements or other business arrangements whereby the LICENSEE markets, promotes
and sells products that may be competitive with the Subject Technology, provided, however, that, except for the rights granted
hereunder, during the term of this Agreement LICENSEE will not sell any products that would compete with the Subject Technology
as it related to the sublingual absorption modalities.


 


IN WITNESS WHEREOF,
the Parties hereto, intending to be legally bound hereby, have each caused to be affixed hereto its or his/her hand and seal the
day indicated.


 





	FUSE SCIENCE INC.	 	MISSION PRODUCT HOLDINGS, INC.	 	 
	 	 	 	 	 	 	 	 	 
	By:	 	/s/ Brian Tuffin	 	By:	 	/s/ Josh Shaw	 	 
	 	 	Brian Tuffin, Chief Executive Officer	 	 	 	Josh Shaw, President